Medtronic Deep Brain Stimulation (DBS) Therapy for Epilepsy Post-Approval Study (EPAS)

Purpose

This is an interventional, prospective, multicenter, open-label, post-market release clinical study with a 3-year follow-up period.

The purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizure reduction in newly implanted patients through 3 years of follow-up.

Who can participate

The intended study population is subjects 18 years and older diagnosed with epilepsy characterized by focal-onset seizures that are refractory to at least 3 AEDs.

Visits

This study requires 10 in-person and telephone visits over 36 months